Cargando…

Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD

Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratiu, Ileana Andreea, Ligor, Tomasz, Bocos-Bintintan, Victor, Mayhew, Chris A, Buszewski, Bogusław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796324/
https://www.ncbi.nlm.nih.gov/pubmed/33374433
http://dx.doi.org/10.3390/jcm10010032
_version_ 1783634655296094208
author Ratiu, Ileana Andreea
Ligor, Tomasz
Bocos-Bintintan, Victor
Mayhew, Chris A
Buszewski, Bogusław
author_facet Ratiu, Ileana Andreea
Ligor, Tomasz
Bocos-Bintintan, Victor
Mayhew, Chris A
Buszewski, Bogusław
author_sort Ratiu, Ileana Andreea
collection PubMed
description Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of death worldwide by cancer is that of the lung, which, in large part, is a result of the disease often not being detected until a late stage. Although COPD and asthma are conditions with considerably lower mortality, they are extremely distressful to people and involve high healthcare overheads. Moreover, for these diseases, diagnostic methods are not only costly but are also invasive, thereby adding to people’s stress. It has been appreciated for many decades that the analysis of trace volatile organic compounds (VOCs) in exhaled breath could potentially provide cheaper, rapid, and non-invasive screening procedures to diagnose and monitor the above diseases of the lung. However, after decades of research associated with breath biomarker discovery, no breath VOC tests are clinically available. Reasons for this include the little consensus as to which breath volatiles (or pattern of volatiles) can be used to discriminate people with lung diseases, and our limited understanding of the biological origin of the identified VOCs. Lung disease diagnosis using breath VOCs is challenging. Nevertheless, the numerous studies of breath volatiles and lung disease provide guidance as to what volatiles need further investigation for use in differential diagnosis, highlight the urgent need for non-invasive clinical breath tests, illustrate the way forward for future studies, and provide significant guidance to achieve the goal of developing non-invasive diagnostic tests for lung disease. This review provides an overview of these issues from evaluating key studies that have been undertaken in the years 2010–2019, in order to present objective and comprehensive updated information that presents the progress that has been made in this field. The potential of this approach is highlighted, while strengths, weaknesses, opportunities, and threats are discussed. This review will be of interest to chemists, biologists, medical doctors and researchers involved in the development of analytical instruments for breath diagnosis.
format Online
Article
Text
id pubmed-7796324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77963242021-01-10 Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD Ratiu, Ileana Andreea Ligor, Tomasz Bocos-Bintintan, Victor Mayhew, Chris A Buszewski, Bogusław J Clin Med Review Lung cancer, chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases that have risen worldwide, posing a major public health issue, encompassing not only physical and psychological morbidity and mortality, but also incurring significant societal costs. The leading cause of death worldwide by cancer is that of the lung, which, in large part, is a result of the disease often not being detected until a late stage. Although COPD and asthma are conditions with considerably lower mortality, they are extremely distressful to people and involve high healthcare overheads. Moreover, for these diseases, diagnostic methods are not only costly but are also invasive, thereby adding to people’s stress. It has been appreciated for many decades that the analysis of trace volatile organic compounds (VOCs) in exhaled breath could potentially provide cheaper, rapid, and non-invasive screening procedures to diagnose and monitor the above diseases of the lung. However, after decades of research associated with breath biomarker discovery, no breath VOC tests are clinically available. Reasons for this include the little consensus as to which breath volatiles (or pattern of volatiles) can be used to discriminate people with lung diseases, and our limited understanding of the biological origin of the identified VOCs. Lung disease diagnosis using breath VOCs is challenging. Nevertheless, the numerous studies of breath volatiles and lung disease provide guidance as to what volatiles need further investigation for use in differential diagnosis, highlight the urgent need for non-invasive clinical breath tests, illustrate the way forward for future studies, and provide significant guidance to achieve the goal of developing non-invasive diagnostic tests for lung disease. This review provides an overview of these issues from evaluating key studies that have been undertaken in the years 2010–2019, in order to present objective and comprehensive updated information that presents the progress that has been made in this field. The potential of this approach is highlighted, while strengths, weaknesses, opportunities, and threats are discussed. This review will be of interest to chemists, biologists, medical doctors and researchers involved in the development of analytical instruments for breath diagnosis. MDPI 2020-12-24 /pmc/articles/PMC7796324/ /pubmed/33374433 http://dx.doi.org/10.3390/jcm10010032 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ratiu, Ileana Andreea
Ligor, Tomasz
Bocos-Bintintan, Victor
Mayhew, Chris A
Buszewski, Bogusław
Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title_full Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title_fullStr Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title_full_unstemmed Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title_short Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD
title_sort volatile organic compounds in exhaled breath as fingerprints of lung cancer, asthma and copd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796324/
https://www.ncbi.nlm.nih.gov/pubmed/33374433
http://dx.doi.org/10.3390/jcm10010032
work_keys_str_mv AT ratiuileanaandreea volatileorganiccompoundsinexhaledbreathasfingerprintsoflungcancerasthmaandcopd
AT ligortomasz volatileorganiccompoundsinexhaledbreathasfingerprintsoflungcancerasthmaandcopd
AT bocosbintintanvictor volatileorganiccompoundsinexhaledbreathasfingerprintsoflungcancerasthmaandcopd
AT mayhewchrisa volatileorganiccompoundsinexhaledbreathasfingerprintsoflungcancerasthmaandcopd
AT buszewskibogusław volatileorganiccompoundsinexhaledbreathasfingerprintsoflungcancerasthmaandcopd